App-Quantinova.ai

Know their numbers: what do ra patients know about their own biomedical data?

T. Ngcozana - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Know your vaccines – a clinical audit on the uptake of vaccinations in systemic lupus erythematosus patients

E.E. Varughese - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Leptin and adiponectin levels in rheumatoid arthritis patients

N. Nicolaou - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Levels of satisfaction with psoriatic arthritis (PSA treatment and associated alignment between rheumatologists and their patients across latin america

F. Zazzetti - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Light at the lower gastrointestinal tract in systemic sclerosis

C.P. Denton - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Hydroxyzine

Linking genetics to t-cell phenotype in jia: rational for il-2 therapy

A. Yarwood - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Interleukin

Local reactivation of glucocorticoids by 11Β-hydroxysteroid dehydrogenase type 1 mediates the development of glucocorticoid-induced bone loss

C Fenton - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Glucocorticoid

Long-term (5-YEAR efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis

A.F. Wells - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Apremilast

Long-term drug survival of etanercept vs other tnf inhibitor therapies in patients with rheumatoid arthritis

P. Emery - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Etanercept

Long-term efficacy and safety of adalimumab by immunosuppressant use in patients with non-infectious uveitis in the visual iii trial

Y. Guex-Crosier - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Uveitis

Mycophenolate mofetil

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF, traps and hids/mkd: results from the pivotal phase 3 cluster trial

F. De Benedetti - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Hyperimmunoglobulinemia D and periodic fever syndrome

canakinumab (SC)

Love your heart, an online, interactive cardiovascular risk assessment programme for people with ra/ia

A.M. Bosworth - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis

A. Deodhar - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

secukinumab

Low inflammation on magnetic resonance imaging in patients with rheumatoid arthritis that achieved sustained clinical remission on adalimumab: data from the predictra study

P. Emery - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

Lower educational levels are associated with a higher risk of rheumatoid arthritis in a southern european nested case-control study

P. de Pablo - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Lumbar muscles stiffness in patients with axial spondyloarthritis is altered in comparison with healthy subjects

I.C. Aranda-Valera - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review

T.J. Bray - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Major cardiovascular events in 434 rheumatoid arthritispatients treated with rituximab from a single-centre

A. Giollo - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemic stroke

Methotrexate

Management of systemic sclerosis (SSC related digital ulcers (DU in expert tertiary centres: results from the analysis of the multicentre observational real-life desscipher/eustar study

J. Blagojevic - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Measurement properties of the minimal disease activity criteria for psoriatic arthritis

L.C. Coates - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Filters

45280 Abstracts